🇺🇸 FDA
Pipeline program

Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

CLOU064O12301

Phase 3 small_molecule active

Quick answer

Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064 for Generalized Myasthenia Gravis is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Generalized Myasthenia Gravis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials